Alopexx Pharmaceuticals, sanofi-aventis deal

Alopexx granted sanofi-aventis an option to license exclusive, worldwide rights to F598. The mAb against poly-N-acetyl glucosamine (PNAG) is expected to begin Phase I testing next year to treat and ...